therapy. Based on distribution studies of radiolabelled WR-2721, cytoprotection of kidney, heart, lung, liver, mucosa and bone marrow is predicted (Utley et al, 1976; Washburn et al, 1976) . Based on the level of the enzyme, γ-glutamyl transpeptidase, necessary for the membrane transport of GSH and radiolabelled GSH, GSH is likely to have protective effects on kidney, liver and peripheral neurons (Romero et al, 1990; Hamers et al, 1993; Ercan et al, 1994) .
In addition, the potential role of these agents in preventing mucosal, cardiac, oto-and neurotoxicity and in preventing the development of secondary malignancies in patients treated with radio-or chemotherapy will be discussed. Special attention will be paid to the characteristics, mechanisms of action, indication for use and the future prospects of these drugs.
WR-2721 CHARACTERISTICS
WR-2721 (amifostine, (S-2-(3-aminopropylamino)-ethylphosphorothioic acid, Ethyol) was developed by the United States Army at the Walter Reed Army Institute of Research in the late 1950s, as part of the Anti-Radiation Drug Development Program to protect soldiers on the battlefield. This agent was selected from 4000 sulfhydryl compounds screened for further clinical evaluation because it was found to be one of the least toxic and most effective. Although it produced only slight effects in cultured cells as a single agent, the addition of alkaline phosphatase markedly increased the protective effects (Calabro-Jones et al, 1985; Mori et al, 1984) . This was because WR-2721 is, in fact, a pro-drug which must be dephosphorylated to the active metabolite WR-1065 (Figure 1 ). The ability of WR-2721 to selectively protect normal tissues against both radiation and chemotherapeutic drugs is accounted for, in part, by higher uptake in normal as compared to tumour tissue (Calabro-Jones et al, 1985) . This differential uptake is probably caused by differences in the microenvironment of alkaline phosphatase in normal and malignant tissue. High concentrations of this enzyme are found in capillaries and arterioles. In contrast, lower levels of alkaline phosphatase in capillaries of malignant tissue are common . In addition, uptake of WR-1065 is highly dependent on pH. Because of their predominantly anaerobic metabolism, tumour tissues tend to have a lower pH than normal tissue. The decreased pH results in significantly reduced uptake of WR-1065 by tumour cells . Also a difference in carrier-mediated transport in tissues may play a role as seen for GSH (Hamers et al, 1993; Grdina et al, 1995) . A difference not only in vascular supply but also in adhesion molecules and transport molecules in vessels might be an explanation for the preferential protection of tumour tissue (Nooijen et al, 1998) . In vitro and in vivo studies in animals have shown that WR-2721 provides selective protection of normal tissue against the toxicity of radiation and numerous chemotherapeutic agents, including alkylating agents, cisplatin, docetaxel and 5-fluorouracil (5-FU). In animal studies an increasing dose of WR-2721 resulted in better radioprotection. When given with cisplatin, the timing of WR-2721 administration might be important, because WR-2721 can form a complex with this drug very rapidly (Thompson et al, 1995) . However, because 90% of the WR-2721 is cleared from the plasma within 6 min after administration of 740 mg m Ϫ2 WR-2721 over 15 min, injection of cisplatin 15 min after WR-2721 administration can be carried out with no WR-2721 or metabolite detected. This permits both drugs to be given without complex formation (Shaw et al, 1986; Korst et al, 1997) . When, however, 910 mg m Ϫ2 WR-2721 is given there is evidence of saturable metabolism . Fifteen minutes after the administration of WR-2721 there is still approximately 15% WR-2721 left in the plasma (range 1-30%, mean 20%). This remnant can form complexes with cisplatin. In carboplatin and paclitaxel in vitro and in vivo no adverse effect on tumour response is found when WR-2721 is given simultaneously (Taylor et al, 1997; Budd et al, 1996) . Based on these results, WR-2721 drug complex formation might be not so important for these two drugs.
WR-2721 is unable to pass through the blood-brain barrier and cannot be used as a protective agent for the brain and spinal cord (Washburn et al, 1976; Millar et al, 1982) . The drug-related toxicities in humans (Kemp et al, 1996) include hypotension (57%), flushing (39%), sneezing (25%), dizziness (11%) and chills (4%). Based on the side-effects, pharmacokinetic interactions and chemotherapeutic or radiotherapeutic schedule used, different concentrations and schedules of WR-2721 are applied. In some regimens, carboplatin is combined with three doses of amifostine because of the high concentration of the active carboplatin species during the first 4 h after administration. In general, for a short and frequent schedule (as radiotherapy), lower WR-2721 concentrations are used. The dose-limiting toxicity is hypotension. In the clinical setting, 200 mg m Ϫ2 to 910 mg m Ϫ2 WR-2721 administered in a 15-min infusion, is a tolerable dose when it is combined with anti-emetics and dexamethasone in the higher WR-2721 concentrations. Premedication with 20 mg dexamethasone intravenously and a serotonin receptor antagonist modifies these effects so that only 1% of infusions are associated with WHO grade 3/4 vomiting and less than 1% of patients require infusion interruption for hypotension (Planting et al, 1996) . No dexamethasone premedication is necessary at a dose of 200 mg m Ϫ2 amifostine, as used in radiotherapy applications. This drug is registered in many countries for the prevention of cisplatin-induced nephrotoxicity. Beside the indications as a chemoprotective agent, WR-2721 is investigated as a bone marrow stimulant in patients with myelodysplastic syndrome. At a dose of 200 mg m Ϫ2 three times a week, haematological activity is shown 
GSH CHARACTERISTICS
GSH is a naturally occurring tripeptide (γ-glutamine-cysteineglycine) and the most abundant intracellular thiol ( Figure 2 ). Although all tissues produce GSH, some synthesize more than others. The liver, for instance, is a net exporter of this peptide. Exogenously administered GSH is reported to increase intracellular GSH levels, but this increase is not caused by the uptake of exogenously administered GSH (Meister, 1983) . This intracellular uptake of GSH from plasma almost always involves its degradation by membrane-bound γ-glutamyl transpeptidase, followed by transport into the cell of the individual amino acids and resynthesis of GSH by γ-glutamylcysteine synthetase and glutathione synthetase. Glutamate is coupled by γ-glutamyl transferase to another amino acid, and this dipeptide is transported across the cell membrane ( Figure 3 ). Glutathione synthetase is not inhibited by glutathione, therefore higher intracellular GSH concentrations can be reached (Meister et al, 1983) . Organs such as kidney, liver and peripheral nerves containing high levels of transpeptidase activity are important scavengers of plasma GSH. The kidney is the most important scavenger, but peripheral nerves also contain quite high levels of γ-glutamyl transpeptidase, indicating they are also capable of importing exogenous GSH. The selective protection of GSH for normal compared to tumour cells is likely related to low membrane γ-glutamyl transpeptidase activity in tumour cells (Hamers et al, 1993) . The organs listed containing a high level of γ-glutamyl transpeptidase activity are those which theoretically could be protected by exogenous GSH administration following radiation or chemotherapy. The half-life of GSH is approximately 15 min after 2000 mg m Ϫ2 GSH. In 90 min following infusion, the urinary excretion of GSH and cysteine was increased 300-fold and tenfold respectively (Aebi et al, 1991) . Compared with a lower dose, the disposition of GSH appears to be dose-dependent and subject to saturation kinetics. Theoretically, the timing of the start of the GSH infusion before the cisplatin might be critical because, like WR-2721, GSH can form a complex with cisplatin. When cisplatin is given 30-60 min after the GSH infusion in a ratio of GSH:CDDP of 30:1 there is protection without interfering with therapeutic activity (Zunino et al, 1989) . In order to maximize the cytoprotective effect of GSH, short cisplatin infusions should be given. In the clinical setting 1500-3000 mg m Ϫ2 GSH is administered i.v. approximately 15 min before chemotherapy (Parnis et al, 1995; Smyth et al, 1997; Bogliun et al, 1996) . In contrast with WR-2721, GSH itself produces no toxicity. This drug is not registered as a chemoprotective agent. In the USA, GSH is also being studied in patients with HIV infection to assess the potential benefit of increasing the abnormally low blood GSH levels found in this setting. In addition, the cytoprotective potential of this drug is being studied with both chemotherapy and radiotherapy in several clinical studies (Di Re et al, 1990 Hamers et al, 1993; Locatelli et al, 1993) .
MECHANISMS OF PROTECTIVE ACTION OF WR-1065 AND GSH
WR-1065 and GSH act as naturally occurring thiols. They prevent cell damage by scavenging of hydroxyl radicals, the chemical repair of DNA radicals by hydrogen atom transfer, the depletion of oxygen as a consequence of thiol oxidation, the protection of key sulfhydryl enzymes through formation of protein-aminothiol mixed disulphides, and the facilitation of DNA repair through binding of the disulphide to DNA resulting in stabilization of DNA and inhibition of replication. WR-2721 has a similarity in structure to polyamines and, also like polyamines, has a high affinity for DNA and polyamine effects on processes related to DNA structure and synthesis (Murley and Grdina, 1995; Murley et al, 1997; Weiss, 1997) . WR-1065 can give, in concentrations from 4 µM in Chinese hamster ovary cells, a delay in the cell cycle and an inhibition of topoisomerase IIα activity . Based on the above described mechanisms, WR-1065 and GSH act as cytoprotective agents following radiation and with chemotherapeutic drugs such as alkylating agents, cisplatin and doxorubicin. The mechanisms for protection of radiation effects by these drugs occur probably by scavenging free radicals, reaction with alkyl groups, prevention of platinum-adduct formation and a faster DNA repair (Treskes et al, 1991) . Preclinical and clinical studies have shown that WR-2721 also provides selective protection of normal tissue against the toxicity of paclitaxel, docetaxel and 5-FU (Wasserman et al, 1981) . In a non-randomized trial, it appeared that amifostine pretreatment has the tendency to reduce the paclitaxel-induced arthralgia, myalgia, myelosuppression and neuropathy (DiPaola et al, 1998) . The mechanism(s) by which it (they) protects against paclitaxel, docetaxel and 5-FU toxicity is not known, or even if they protect in the clinic. In addition, confirmatory randomized data are required before it can be stated that amifostine provides protection for the effects of these agents in the clinic. It may be that a faster DNA repair is responsible for the protective activity of 5-FU.
CLINICAL RESULTS OF RADIO-AND CHEMOTHERAPY PROTECTION BY WR-2721
In Table 1 , different comparative clinical trials using WR-2721 as radio-and chemoprotective agent are presented; unfortunately, most studies are small. Most comparative trials showed WR-2721 to reduce the severity and/or incidence of granulocytopenia and thrombocytopenia observed after cisplatin (CDDP) plus cyclophosphamide or cyclophosphamide alone compared with a control group or in patients who crossed to chemotherapy alone. The largest randomized trial is that of Kemp et al (1996) . In total, 242 patients with advanced epithelial ovarian cancer were randomized to treatment with cyclophosphamide (1000 mg m Ϫ2 ) plus CDDP (100 mg m Ϫ2 ) with or without amifostine (910 mg m Ϫ2 ), every 3 weeks for 6 cycles. WR-2721 was shown to reduce the renal toxicity from cisplatin given in a dose of 100 mg m Ϫ2 CDDP. The survival in the two groups was similar, providing reassurance that WR-2721 did not cause tumour protection. As a result of the reduction in renal, haematologic and neurotoxicity only 9% of patients in the WR-2721 arm discontinued chemotherapy, compared with 24% in the control arm. Liu et al (1992) published a randomized study in 100 patients with radiotherapy (entire pelvis: 4500 cGy, conedown: 720 cGy) with or without WR-2721 (340 mg m Ϫ2 ) in patients with advanced rectal cancer. The radiation toxicity was scored on the Radiation Therapy Oncology Group (RTOG) scale. A reaction was considered acute if it occurred within 105 days after the first radiotherapy day. No moderate or severe late toxicity from radiation was seen in the normal tissues in patients who received WR-2721. Five patients treated with radiotherapy alone had a moderate or severe toxicity to one or more of the following organs: skin, genitourinary or lower gastrointestinal tract. The WR-2721 was administered i.v. before each radiotherapy session. Although there was a significant reduction in late radiation-induced toxicity, there was no effect on acute toxicity in this group of rectal cancer patients. There was no evidence of tumour protection by WR-2721: 16% of the patients randomized to the WR-2721 group had a complete response compared with 10% in the group with radiotherapy only. This difference is, however, not significant because of the small numbers in each group; this is due to the fact that only 60% of the patients were evaluable. In a phase II study (Buntzel et al, 1998) in patients with head and neck cancer treated with radiotherapy and carboplatin, WR-2721 was administered i.v. in 25 patients compared with 14 patients in the control group. A reduced platelet toxicity and mucositis was found in the WR-2721-treated group. Brizel et al (1998) showed a reduction in the acute radiationinduced toxicity (xerostomia) in patients with head and neck cancer in the WR-2721-treated group compared with the control group. To balance the overall effect of WR-2721, one has to take in toaccount, on one hand, the reduction in radiotherapy-induced toxicity and a small reduction of haematological and renal toxicity, and on the other hand, the side-effects of the WR-2721 infusion. However, with an improved premedication regimen, WR-2721 is tolerable.
CLINICAL RESULTS OF CHEMOTHERAPY PROTECTION BY GSH
In Table 2 different comparative clinical trials using GSH as a chemoprotective agent are presented. For GSH, a protection of cisplatin-induced toxicity is noted in ovarian cancer comparable with that produced by WR-2721 (Smyth et al, 1997) . In this randomized, double-blind study, 151 patients with ovarian cancer were treated with 100 mg m Ϫ2 with or without GSH (3 g m Ϫ2 ), every 3 weeks for 6 cycles. Nephrotoxicity occurred in 39% who received GSH versus 49% controls, and caused failure to complete protocol in 11/74 versus 26/77. In addition, quality of life was assessed, which showed a significant reduction in depression in the GSH-treated group. No tumour protection was found.
A small, randomized study with cisplatin with and without GSH has been published by Boglium et al (1996) . In this study, 54 patients with ovarian cancer were treated with 50 or 75 mg m Ϫ2 CDDP every 3 weeks for 9 or 6 courses respectively, with or without 2.5 g m Ϫ2 GSH. In a small group with a cumulative dose of 500-675 mg m Ϫ2 (ten patients without GSH and 13 patients with GSH), there was a trend toward less severe neurotoxicity. No difference in non-neurological side-effects were found. It can be concluded that, taken in account with the results of the phase II studies, GSH shows protective activity against cisplatin-induced renal toxicity.
In Table 3 , ongoing clinical trials with WR-2721 are listed (PDQ clinical trial search), no trials are found with GSH in the PDQ clinical trial search. For the future it would be interesting to study the effect on the quality of life of both drugs (WR-2721 and GSH) after chemotherapeutic and radiation regimens. An increase in quality of life is expected when it is possible to prevent mucositis, neurotoxicity, ototoxicity, cardiac failure and the development of secondary tumours. For evaluation of protection, objective tests are necessary.
DIFFERENCES BETWEEN THE CHEMOPROTECTIVE EFFECTS OF WR-2721 AND GSH
The basic structure of both sulfhydryl-containing drugs is completely different. The polyamine-like structure of WR-2721 suggests it may have a greater protective effect on DNA. Different organs are protected by WR-2721 and GSH. Based on the distribution studies of radioactive WR-2721 and GSH (Washburn et al, 1976; Ercan et al, 1994) , radio-and chemotherapy protection for kidney, heart, lung, mucosa, liver and bone marrow is expected for WR-2721, and for GSH, protection is expected for kidney, liver and urinary bladder. Based on the level of the enzyme, γ-glutamyl transpeptidase necessary for the membrane transport of GSH, and according to animal data, GSH is likely to have a protective effect on peripheral neurons (Romero et al, 1990; Hamers et al, 1993) .
Based on the available laboratory data, WR-2721 shows protection against radiotherapy, cisplatin, alkylating agents, 5-FU and taxanes, and GSH shows protection against alkylating agents and cisplatin. Clinical data on all except radiation, alkylation and cisplatin/ CBDCA are weak. Clinical data from WR-2721 and GSH show protection against renal and bone marrow toxicity. Importantly, GSH can supply this protection without major side-effects. However, on the above mentioned preclinical data, WR-2721 has, theoretically, an extended clinical application.
FUTURE PROSPECTS

Local effects on mucous-and visceral membranes
Oral mucositis and rectal wall injury are important chemo-and radiation treatment-related toxicities. Local application of WR-2721 to the small bowel mucosa of rats before radiation provides protection and this benefit is amplified when WR-2721 is in an alkaline medium (Delaney et al, 1994) . Local application of WR-2721 rectally in 21 patients prior to each fraction of pelvic radiation did not show a protective effect when compared to historical controls treated without WR-2721. This was in spite of a high concentration of alkaline phosphatase in the rectal wall (Ben-Josef et al, 1995) . The reasons for failure of this drug to protect the rectosigmoid mucosa may be related to the method of administration: the rectum was not empty, only 30 ml were given and radiation was given until 45 min later (Montana et al, 1992) . In a phase II study in patients with head and neck cancer having local radiotherapy, less mucositis was found in the group that received WR-2721 i.v. (Buntzel et al, 1998) . Prevention of oral mucositis with local application of WR-2721 has not been investigated to date. The taste of WR-2721 (20 mg ml Ϫ1 ) is acceptable (personal observation), but it is uncertain if the activity of alkaline phosphatase in the mouth or saliva is sufficient to produce WR-2721 to the active WR-1065 component. Alkaline phosphatase is present in the oral mucosa, but the concentration is ten times lower than that of the rectal mucosa. However, the concentration of alkaline phosphatase is probably not the only factor necessary to convert WR-2721 because, based on in vitro experiments, myocytes have a low degree of alkaline phosphatase but can convert WR-2127 to the active compound (Dorr, 1996) . Local application of GSH is also interesting to investigate, although the effect is questionable because the γ-glutamyl-transferase concentration in the oral mucosa and saliva is low (Sajjan et al, 1991; Schwint et al, 1992) .
Recently, Alberts et al (1996) showed, in ovarian cancer, that intraperitoneal (i.p.) cisplatin significantly improves survival and has overall a significantly lower toxicity compared to i.v. cisplatin, but in the i.p. group an increase of abdominal pain and dyspnoea was found. Given WR-2721 i.v., only 1% of the dose appears in the ascites (Van der Vijgh and Kerst, 1996) , therefore WR-2721 might be considered for i.p. administration to circumvent intraabdominal distress. Based on monkey experiments of i.p. WR-2721, where 100% of the radioactive WR-2721 was found systemically with only a delay of approximately 10 min compared with i.v. administration (Mangold et al, 1989) , it is likely that sideeffects of i.p. WR-2721 would be similar to i.v. administration.
Neurotoxicity and ototoxicity
Neurotoxicity and ototoxicity are important irreversible problems in some curatively treated patients, notably those with germ cell tumours. Neuropathy has been reported to occur in 30-100% of patients with germ cell tumours treated with cisplatin and is irreversible in 30-50% of the patients (Alberts and Noel, 1995; De Wit, 1995) . A trial of WR-2721 in this group of patients has not been undertaken, perhaps because of concern over tumour protection in this curable disease and the knowledge that testicular germ cell tumours can express alkaline phosphatases. However, in an animal model with an alkaline phosphatase-positive tumour, no evidence is found for tumour protection by WR-2721 (Dunn et al, 1996) . In Wistar rats, cisplatin-induced neuropathy was reduced after a dose of 200 mg GSH per kg body weight (Hamers et al, 1993) . In hamsters, WR-2721 did not show any chemoprotection in combination with cisplatin on the cochlea (Kaltenbach et al, 1997) . However, in a phase I study with high-dose cisplatin, radiotherapy and WR-2721 compared with a control group, there is an indication of a decrease in ototoxicity (Rubin et al, 1995) . Recently (McGuire et al, 1996) , the combination of cisplatin and paclitaxel has been shown to be very active in ovarian cancer, with an increase in median survival of 1.5 years, compared to the standard regimen of cyclophosphamide and cisplatin. Since both cisplatin and paclitaxel are known to be neurotoxic, the use of effective chemoprotective agents may increase the quality of life in patients treated with this regimen. Investigation of thiol compounds with this combination would therefore be of interest. Sensitive objective tests of neurologic function will be important to accurately document the impact of cytoprotective agents in this setting.
Cardiac failure
Cardiac failure after chemo-and radiotherapy may arise as a late complication 5-10 years after treatment, often occurring in the subset of relatively young patients successfully 'cured of the cancer' (Lipschulz et al, 1991; Steinherz and Yahalon, 1993; Gyenes et al, 1996; Shapiro and Henderson, 1994) . Dexrazoxane (ICRF-187, Zinecard, ADR-529), another chemoprotective agent, has been shown to significantly decrease anthracycline-related cardiotoxicity (Swain et al, 1997) , without a decrease in survival. However, the patients treated had metastatic breast cancer with a median survival of only 5 months. There are only a few publications of the effect of thiols in this setting (Dorr, 1996) . In vitro experiments with cardiac myocytes showed a decrease in the doxorubicin-related toxicity after incubation with WR-2721. An interesting observation in the WR-2721-treated cells was the detection of an increase in the GSH content (Dorr, 1996) . No clinical studies with WR-2721 and GSH as protectors of radio-and chemotherapy-induced cardiac toxicity have been carried out. Cardiac failure after chemotherapy is often a late symptom. Therefore, objective early tests to demonstrate cardiac dysfunction have to be developed to evaluate the effect of protective agents at an early stage. In order to develop objective tests to evaluate cardiotoxicity, an awareness of different types of cardiotoxicity caused by chemo-and radiotherapy is required. Cardiotoxicity can be divided into three types of toxicity: (1) due to myocardial damage, (2) due to vascular damage, (3) due to activation-and conduction system damage (neurotoxicity). For the myocardial damage, a MUGA scan is a reasonable objective test. For the other two types of toxicities, objective early tests have to be developed.
Therapy-induced secondary cancer
The use of radio-and chemotherapy has placed a large number of patients at potential risk for developing a treatment-related malignancy. On the other hand, it is becoming more apparent that host factors, for example a germline mutation in p53, can also increase the risk of developing a second tumour.
In vitro WR-1065 showed a reduction in radio-and chemotherapy-induced mutation in hamster cells (Hill et al, 1986; , and reduced the protooncogene c-myc expression (Liu et al, 1997) and delayed a cell cycle progression and build-up cells in the G2 phase of the cell cycle . Pretreatment with amifostine reduced mutation frequency in cells from mice given radiation, cisplatin or cyclophosphamide Grdina et al, 1992) . WR-2721 has the ability to protect against radiation carcinogenesis. In mice treated with WR-2721, 26% of radiation-induced sarcomas developed compared with 87% in the mice exposed to radiation only (Milas et al, 1984) . In the clinical setting, an advantage of WR-2721 and GSH may therefore be their potential to reduce the development of radioand chemotherapy-induced secondary tumours.
CONCLUSION
WR-2721 can provide selective protection against platinum and alkylating agents related to renal-and bone marrow toxicity and radiation-induced toxicity. Based on the randomized study of Smyth et al (1997) and phase II studies, GSH has the same protective profile as WR-2721 when given prior to cisplatin. GSH has no significant side-effects and is therefore a potential alternative for WR-2721. An important remark concerning these radio-and chemotherapy protective agents is that, when given extracellularly, no tumour resistance to radio-and chemotherapy has been noticed. Although these drugs show protection against chemotherapyrelated renal-and bone marrow toxicity, and WR-2721 shows a protection against the toxicity of radiotherapy, the magnitude of this protection has no impact on the standard chemotherapeutic regimens. New studies should focus on the magnitude of clinical cytoprotection and the real clinical benefit. These agents may be useful in increasing the quality of life by decreasing mucositis, neurotoxicity, ototoxicity and cardiac toxicity, but this is speculative and studies to confirm this are needed. For preventing mucositis without the side-effect of systemically administered WR-2721, local application would be interesting to study.
